Shopping Cart
- Remove All
Your shopping cart is currently empty
FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor targeting the secondary mutations D835Y/F691L in the FLT3 tyrosine kinase domain, with IC50 values of 1.5 and 9.7 nM, respectively. This compound is applicable in research related to acute myeloid leukemia.

| Description | FLT3D835Y/F691L-IN-1 (compd 8v) is an orally active inhibitor targeting the secondary mutations D835Y/F691L in the FLT3 tyrosine kinase domain, with IC50 values of 1.5 and 9.7 nM, respectively. This compound is applicable in research related to acute myeloid leukemia. |
| In vitro | FLT3D835Y/F691L-IN-1 (0.16-100 nM, 4 h) inhibits the phosphorylation of FLT3 and cell cycle-associated proteins CDK4/6 and Cyclin D3. It also suppresses the proliferation of transfected Ba/F3 cells with FLT3-ITD, FLT3-ITD-D835Y, FLT3-ITD-F691L, FLT3-ITD-D835Y-F691L mutations and the MV4-11 acute myeloid leukemia cell line, with IC50 values of 12.2, 10.5, 24.6, 16.9, and 6.8 nM, respectively. |
| In vivo | FLT3D835Y/F691L-IN-1, administered orally at a dosage of 30 mg/kg daily for 28 days, effectively reduces tumor volume in mice with Ba/F3-FLT3-ITD-D835Y xenografts. |
| Formula | C26H37N7O4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.